<DOC>
	<DOCNO>NCT00858572</DOCNO>
	<brief_summary>The purpose study characterize safety efficacy STA-9090 ( ganetespib ) subject hematologic malignancy .</brief_summary>
	<brief_title>STA-9090 Treatment AML , CML , MDS Myeloproliferative Disorders</brief_title>
	<detailed_description />
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>Inclusion Criteria Males females 18 year older Eligible subject must one follow relapsed refractory hematologic malignancy : AML , MDS , CML , myeloproliferative disorder define protocol Must acceptable organ function screening define protocol Exclusion Criteria Pregnant breastfeed woman Patients must meet washout period prior chemotherapy radiation History stroke within 6 month treatment Poor venous access study drug administration Treatment chronic immunosuppressant Other severe acute/chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Synta</keyword>
	<keyword>STA-9090</keyword>
	<keyword>AML</keyword>
	<keyword>CML</keyword>
	<keyword>MDS</keyword>
	<keyword>myeloproliferative disorder</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>ganetespib</keyword>
</DOC>